What's Next in Immunotherapy?

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

During the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs, Capitini emphasized that all cancers should eventually find benefit in immunotherapy. With expansion in renal cell carcinoma (RCC), lung cancer and head and neck cancer, that change may be underway.

Related Content:

CURE TVSkin CancerKidney CancerHead & Neck CancerImmunotherapy
Early-Phase Trial to Study Novel Drug, With or Without Keytruda, in Solid Cancers
Catching the Importance of Skin Cancer Awareness and Prevention
Telaglenastat-Cabometyx Combination May Not Improve Survival in Pretreated Kidney Cancer Compared With Cabometyx Alone